IRLAB's candidate drug, mesdopetam, demonstrated antipsychotic properties in an advanced preclinical Parkinson's disease psychosis model, outperforming clozapine and pimavanserin.
IRLAB Therapeutics announced that its candidate drug, mesdopetam, has demonstrated antipsychotic properties in an advanced preclinical model of Parkinson's disease psychosis (PD-P). The research was conducted in collaboration with Lund University and reported in the journal Neurotherapeutics. Mesdopetam's effects were compared with clozapine and pimavanserin, both clinically used to alleviate PD-P.
March 19, 2024
4 Articles